BEAM vs. TWST, FUSN, RXRX, INBX, DNA, SANA, ADMA, NMRA, KYMR, and NTLA
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Twist Bioscience (TWST), Fusion Pharmaceuticals (FUSN), Recursion Pharmaceuticals (RXRX), Inhibrx (INBX), Ginkgo Bioworks (DNA), Sana Biotechnology (SANA), ADMA Biologics (ADMA), Neumora Therapeutics (NMRA), Kymera Therapeutics (KYMR), and Intellia Therapeutics (NTLA). These companies are all part of the "medical" sector.
Twist Bioscience (NASDAQ:TWST) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
99.7% of Beam Therapeutics shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by insiders. Comparatively, 4.2% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Twist Bioscience currently has a consensus target price of $42.50, indicating a potential upside of 2.66%. Beam Therapeutics has a consensus target price of $40.18, indicating a potential upside of 80.67%. Given Twist Bioscience's higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Twist Bioscience.
Beam Therapeutics has a net margin of -35.09% compared to Beam Therapeutics' net margin of -69.24%. Twist Bioscience's return on equity of -15.90% beat Beam Therapeutics' return on equity.
In the previous week, Twist Bioscience had 22 more articles in the media than Beam Therapeutics. MarketBeat recorded 42 mentions for Twist Bioscience and 20 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.31 beat Twist Bioscience's score of 0.26 indicating that Twist Bioscience is being referred to more favorably in the media.
Beam Therapeutics has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
Twist Bioscience received 48 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 56.69% of users gave Twist Bioscience an outperform vote while only 51.25% of users gave Beam Therapeutics an outperform vote.
Twist Bioscience has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500.
Summary
Beam Therapeutics beats Twist Bioscience on 11 of the 18 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
